Format

Send to

Choose Destination
J Infect. 2015 Mar;70(3):288-98. doi: 10.1016/j.jinf.2014.10.015. Epub 2014 Nov 6.

Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection.

Author information

1
Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", 00100 Rome, Italy.
2
Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, 1000 Amsterdam, The Netherlands.
3
Yale University, New Haven, CT 06520 United States.
4
University Hospital of Rome "Tor Vergata", 00100 Rome, Italy.
5
"L. Sacco" Hospital, 20157 Milan, Italy.
6
Microbiology and Virology Unit, "S. Pertini" Hospital, 00100 Rome, Italy.
7
"La Sapienza" University 00100 Rome, Italy.
8
Virology Laboratory, Centre Hospitalier Régional et Université "Victor Segalen", CHU de Bordeaux, 33300 Bordeaux, France.
9
"Santa Maria Annunziata" Hospital, 50100 Florence, Italy.
10
Institute of Virology, University Hospital, 45147 Duisburg-Essen, Germany.
11
Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", 00100 Rome, Italy; University Hospital of Rome "Tor Vergata", 00100 Rome, Italy.
12
Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", 00100 Rome, Italy. Electronic address: valentina.svicher@uniroma2.it.

Abstract

BACKGROUND:

To define HBsAg-mutations correlated with different serum HBV-DNA levels in HBV chronically-infected drug-naive patients.

METHODS:

This study included 187 patients stratified into the following ranges of serum HBV-DNA:12-2000 IU/ml, 2000-100,000 IU/ml, and >100,000 IU/ml. HBsAg-mutations were associated with HBV-DNA levels by applying a Bayesian-Partitional-Model and Fisher-exact test. Mutant and wild-type HBV genotype-D genomes were expressed in Huh7 cells and HBsAg-production was determined in cell-supernatants at 3 days-post-transfection.

RESULTS:

Specific HBsAg-mutations (M197T,-S204N-Y206C/H-F220L) were significantly correlated with serum HBV-DNA <2000 IU/ml (posterior-probability>90%, P < 0.05). The presence of Y206C/H and/or F220L was also associated with lower median (IQR) HBsAg-levels and lower median (IQR) transaminases (for HBsAg:250[115-840] IU/ml for Y206C/H and/or F220L versus 4300[640-11,838] IU/ml for wild-type, P = 0.023; for ALT:28[21-40] IU/ml versus 53[34-90] IU/ml, P < 0.001). These mutations were localized in the HBsAg C-terminus, known to be involved in virion and/or HBsAg secretion. The co-occurrence of Y206C + F220L was found significant by cluster-analysis, (P = 0.02). In addition, in an in-vitro model Y206C + F220L determined a 2.8-3.3 fold-reduction of HBsAg-amount released in supernatants compared to single mutants and wt (Y206C + F220L = 5,679 IU/ml; Y206H = 16,305 IU/ml; F220L = 18,368 IU/ml; Y206C = 18,680 IU/ml; wt = 14,280 IU/ml, P < 0.05).

CONCLUSIONS:

Specific HBsAg-mutations (compartmentalized in the HBsAg C-terminus) correlated with low-serum HBV-DNA and HBsAg-levels. These findings can be important to understand mechanisms underlying low HBV replicative potential including the inactive-carrier state.

KEYWORDS:

HBV; HBsAg; Serum HBV-DNA; Virion maturation

PMID:
25452041
DOI:
10.1016/j.jinf.2014.10.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center